TO THE EDITOR
Chronic myelogenous leukemia (CML) is the clonal expansion of hematopoietic progenitor cells. The chronic phase of expanded clonal myelopoiesis lasts several years, but commonly evolves slowly into the accelerated phase and then finally to a blast crisis, which is usually derived from a Philadelphia chromosome (Ph 1 )-positive clone. Natural killer (NK) cells decrease in number and in function during CML progression from chronic phase of blastic crisis 1 and become Bcr/Abl þ late in the disease course.
2 Furthermore, very rare cases of blast crisis associated with CML showing features similar to those described in acute myeloid/NK cell precursor leukemia have been described. Here, we report two sequential CML cases that developed Ph 1 -negative myeloid/NK cell precursor leukemia during the chronic phase.
Patient 1 was a 78-year-old female diagnosed as chronic phase CML in January 2000. She was administered interferon (IFN) alpha beginning in January 2000. From then until October 2002, when a major cytogenetic response was observed, she was also given hydroxyurea simultaneously. However, Ph 1 increased to 34.5% according to fluorescent in situ hybridization (FISH) 2 months before she was admitted to our hospital. Although Imatinib mesylate treatment was started, it caused a severe skin rash and was discontinued. At 2 weeks before admission, Ph 1 increased to 55.5% by FISH (Table 1) . She was admitted to our department in March 2004 because of fever, anemia, and thrombocytopenia. On admission, a blood examination revealed a white blood cell count of 6.5 Â 10 9 /l, myelocytes 0.3%, band form 7.7%, segmented form 63.3%, lymphocytes 7.0%, monocytes 20.0%, eosinophils 0.7%, basophils 1.0%, blast 0%, hemoglobin (Hb) 9.6 g/dl, and platelets 126 Â 10 9 /l. An ultrasound examination of the patient's abdomen demonstrated no enlarged organs. Bone marrow aspiration showed hypercellular marrow with neither dysplasia nor any blasts. Cytogenetic analysis indicated Ph 1 in 14 (70%) of 20 metaphases and normal karyotype in six (30%) ( Table 1) , indicating no transformation into a blast crisis. At 3 weeks after admission, the patient experienced a worsening of both anemia (Hb 6.5 g/dl) and thrombocytopenia (platelets 30 Â 10 9 /l) ( Table 1) . Her neutrophilic alkaline phosphatase (NAP) score was 42. Bone marrow aspiration demonstrated hypercellular marrow with 69.9% myeloperoxidase-negative blasts ( Figure 1a) . By CD45 blast gating methods, the blasts were positive for CD7, CD13, CD33, CD56, and HLA-DR, but negative for CD34 and other lymphoid antigens. These results suggested the rapid evolution of myeloid/NK cell precursor leukemia.
3 Southern blot analysis demonstrated clonal rearrangement of the T-cell receptor (TCR) b chain, while no rearrangement of immunoglobulin heavy chain genes were detected. Unexpectedly, cytogenetic analysis indicated 45, XX, add(4)(p31), del(7)(p13), add(9)(p24), der(17;18)(q10;q10), and their associated aberrations in 17 (85%) of 20 metaphases, Ph 1 in only one (5%), and normal karyotype in two (10%) metaphases, as shown. The patient underwent chemotherapy consisting of vincristine, prednisolone, and adriamycin, and the results were marginally effective. Finally, she developed fever and obstructive jaundice. She died of disease progression and pneumoniae 1 month after admission. At autopsy, her bone marrow, liver and spleen were full of blasts, but no tumor formation was observed. Staphylococcus aureus and Candida glabrata were detected in arterial blood and bronchus, indicating the presence of sepsis and pneumoniae. Patient 2 was a previously healthy 69-year-old male who was referred to our hospital in June 2004 because of leukocytosis. A blood examination revealed a white cell count of 23.1 Â 10 9 /l, myeloblasts 2.7%, myelocytes 8.7%, metamyelocytes 3.3%, band form 2.0%, segmented form 62.7%, lymphocytes 12.0%, eosinophils 1.0%, basophils 1.6%, Hb 16.6 g/dl, and platelets 537 Â 10 9 /l (Table 2 ). Cytogenetic analysis indicated Ph 1 in 20 (100%) of 20 metaphases, and bone marrow aspiration was consistent with chronic phase CML. An ultrasound examination of the patient's abdomen demonstrated no enlarged organs. Although Imatinib mesylate was started, the patient discontinued it after 10 days due to severe edema. Blasts increased gradually, and both the anemia and thrombocytopenia worsened (Table 2) . Three weeks later after first visit, he was admitted to our department for treatment of purpura. On admission, a blood examination revealed a white cell count of 81.1 Â 10 9 /l, myelocytes 0.3%, metamyelocytes 1.3%, band form 1.3%, segmented form 6.3%, lymphocytes 7.3%, monocytes 0.7%, eosinophils 0.7%, basophils 0.7%, blast 81.4%, hemoglobin (Hb) 10.6 g/dl, and platelets 32 Â 10 9 /l. Bone marrow aspiration showed hypercellular marrow with 89.8% myeloperoxidase-negative blasts (Figure 1b) . By CD45 blast gating methods, the blasts were positive for CD7, CD13, CD33, CD34, CD56, and HLA-DR but negative for other lymphoid antigens. This suggested the evolution of myeloid/NK cell precursor leukemia. Cytogenetic analysis indicated 46, XY, del(7)(p11), add(11)(q13) in 13 (65%) of 20 metaphases, 46, XY, add(7)(p11) in two (10%), Ph 1 in one (5%), and normal karyotype in four (20%) metaphases. Bcr/abl fused genes were detected in 4.5% of cells examined by FISH. The patient is now undergoing chemotherapy consisting of cytarabine and idarubicine.
In most cases of CML, blasts transforming from CML are characterized cytogenetically as abnormalities associated with Ph 1 , such as a deleted chromosome 22, double Ph 1 , an additional aberration, or more complex rearrangements. In both Patients 1 and 2, cytogenetic analysis showed Ph 1 in only 5% of 20 metaphases, and complex abnormalities without Ph 1 evolved predominantly. In Patient 2, FISH analysis showed only 4.5% positive cells for bcr/abl fused genes despite the evolution of the blasts. These data suggest that both cases developed Ph 1 -negative myeloid/NK precursor cell leukemia during chronic phase CML. Although there have been a few descriptions concerning blastic transformation into myeloid/NK cell precursor leukemia, the blasts were cytogenetically Ph 1 -positive in those cases. 4, 5 To our knowledge, the cases presented here are the first of Ph 1 -negative myeloid/NK cell precursor leukemia during chronic phase CML. Two cases with Ph 1 -negative leukemic transformation in Ph 1 -positive CML have been reported in the literature to date. 6, 7 In those reports, Ph 1 -negative AML, but not myeloid/NK cell precursor leukemia, arose after busulfan and/or IFN treatment for Ph 1 -positive CML. There is increasing evidence that novel cytogenetic abnormalities or AML may develop in patients undergoing IFN therapy for CML or hairy cell leukemia. 8, 9 Furthermore, a case with secondary myeloid/NK cell precursor leukemia following essential thrombocythemia treated with nitrosourea was reported previously.
10 From these reports, we can infer that Patient 1 may have developed therapy-related leukemia. However, as Patient 2 had no previous history of exposure to radiation or antitumor agents, the pathogenesis of leukemia progression is unclear. The ability to know whether or not blasts are derived from CML clones may be very important in determining appropriate treatment. The therapeutic effect of the chimeric anti-CD20 IgG1 rituximab (Mabthera, Rituxan) which is widely used in the treatment of B-cell non-Hodgkin's lymphomas involves the triggering of Fcg receptor-positive effector cells and/or the activation of complement. 1 The clinical value in follicular lymphoma of polymorphisms of the activating members of the FcgR family, FcgRIIIA (CD16) and FcgRIIA (CD32) expressed on NK and macrophages, suggests that antibody-dependent cell-mediated cytotoxicity (ADCC) may be the major effector mechanism.
2, 3 We have shown that, although downregulated in reactive germinal center B cells, FcgRIIB is expressed by one-fifth of diffuse large B-cell lymphomas (DLBCL).
4 Expression of FcgRIIB on tumor cells could interfere with rituximab action. It may bind the Fc portion of the therapeutic antibody and thus compete for binding with the activating FcgR or with complement which are required for ADCC and CDC, respectively. In addition, FcgRIIB being an inhibitory receptor, 5 its expression may have a direct negative effect on tumor cells upon ligation with immune complexes. To address the questions of the prognostic impact of FcgRIIB expression and its potential influence on rituximab efficacy, we have investigated retrospectively 234 patients included in the LNH-98.5 from the GELA (Groupe d'Etude des Lymphomes de l'Adulte) which has shown that the combination of rituximab and CHOP (R-CHOP) was more effective than CHOP alone. 6 From the 399 patients included in the LNH-98.5 trial, Bcl-2 expression has been previously analyzed in a subgroup of 292 patients, showing that rituximab overcomes resistance to chemotherapy linked to Bcl-2 overexpression.
7 Among this subgroup, immunohistochemical analysis was performed in 234 patients on deparaffinized and microwave pretreated slides, as previously described.
4 Analysis of FcgRIIB expression was performed without knowledge of the clinical data, all positive and doubtful cases being independently analyzed by two pathologists. Samples were considered as positive when at least 10% of tumor cells showed a strong membrane staining. However, results led to a clear-cut positive pattern, with the majority of tumor cells strongly positive at their plasma membrane.
Among the 234 cases, 42 (18%) showed a strong plasma membrane expression of FcgRIIB (Figure 1 ) on tumor cells (FcgRIIB þ ). FcgRIIB expression was imbalanced within the two arms of treatment, the FcgRIIB þ cases being more frequent in the R-CHOP arm (31/129, 24%) than in the CHOP one (11/105, 11%) (P ¼ 0.007). This imbalance was even more obvious in the stage II subgroup, since 11 out of the 13 FcgRIIB þ cases (85%) received R-CHOP. This imbalance not explicable by a systematic error since the series was issued from a randomized trial and the slides analyzed randomly, without knowledge of clinical data or arm of treatment. There was no linkage between FcgRIIB expression and Bcl-2 (P ¼ 0.3). Similarly, no significant association has been shown between FcgRIIB expression and the other clinical or biological parameters (detailed in Table 1 ).
FcgRIIB expression had no influence on response to therapy (Table 1) nor on survival duration in univariate analysis (median follow-up: 37 months). In the whole population, the 2-year survival estimates were 64% (confidence interval (CI 95% 57-71) vs 67% (CI 95% 52-81) for overall survival (OS) (P ¼ 0.58) and 49% (CI 95% 42-56) vs 55% (CI 95% 40-70) for event-free survival (EFS) (P ¼ 0.38), when comparing FcgRIIB-and FcgRIIB þ cases, respectively. Also, there was no prognostic impact when we analyzed separately both treatment arms. The 2-year OS was 59% (CI 95% 49-68) for FcgRIIB-and 55% (CI 95% 25-84) for FcgRIIB þ cases (P ¼ 0.68) in the group of patients who received CHOP. For R-CHOP arm, the 2-year OS was 69% (CI 95% 60-79)
